Blog

Mark Stewart: Liquid Biopsies Coming of Age: Biology, Emerging Technologies, and Clinical Translation.

Photo of Mark Stewart taken from aacr.org

Sep 27, 2023, 22:25

Mark Stewart: Liquid Biopsies Coming of Age: Biology, Emerging Technologies, and Clinical Translation.

Mark Stewart, Vice President, Science Policy at Friends of Cancer Research, made the following post on LinkedIn:

“I’m excited to share a new special collection available through the Society for Immunotherapy of Cancer’s (SITC) Journal for ImmunoTherapy of Cancer: Liquid Biopsies Coming of Age: Biology, Emerging Technologies, and Clinical Translation.

Dr. Valsamo Anagnostou and I served as special editors and coordinated the development of a series of articles over the past year and half that are authored by leading voices in cancer biology, technology development, regulatory science, and immuno-oncology. The series consists of 5 review articles and 5 companion viewpoint letters.

Series Editorial: Liquid biopsies coming of age: biology, emerging technologies, and clinical translation- An introduction to the JITC expert opinion special review series on liquid biopsies – click here.

Review: Cell-free DNA approaches for cancer early detection and interception – click here.

Viewpoint: Brave new world of cfDNA-omics for early cancer detection – click here.

Review: Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA – click here.

Viewpoint: Challenges in the implementation of ultrasensitive liquid biopsy approaches in precision oncology – click here.

Review: Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation – click here.

Viewpoint: Comments on roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation – click here.

Review: Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy – click here.

Viewpoint: Next-generation ctDNA-driven clinical trials in precision immuno-oncology – click here.

Review: Regulatory implications of ctDNA in immuno-oncology for solid tumors – click here.

Viewpoint: Liquid biopsies, are we ready for prime time? – click here.

Thank you to the JITC editorial team and authors for contributing to an incredible body of work to support continued research and validation of the use of liquid biopsies to deliver the earliest, best clinical care with precision.”

Source: Mark Steward/LinkedIn